



Background

Experts provide solutions to complex cases not addressed by high quality evidence They intuitively retrieve patterns from years of experience to make treatment decisions Short of personal consults, there is no way to access this vast experiential knowledge Navya and Tata Memorial Centre designed a machine learning solution

To build the Experience Engine (XE), a machine learning solution to:

Machine Learning Methodology for the Experience Engine (XE)

Step 1: Structured database of experiential knowledge





Step 3: Patient record retrieval by learned similarity



© Tata Memorial Centre, Mumbai, India & Navya Network, Cambridge, MA

AGE: 42 Grade: III Albumin: 3.4

San Antonio Breast Cancer Symposium - December 6-10, 2016

Building An Experience Engine To Make Cancer Treatment Decisions Using Machine Learning

N Ramarajan¹, S Gupta², P Perry¹, G Srivastava¹, A Kumbla³, J Miller³, N Feldman³, NS Nair², RA Badwe² 1. Navya Network, Cambridge (MA); 2. Tata Memorial Centre, Mumbai (India); 3. University of California Los Angeles - Olive View Medical Center, Los Angeles (CA)

Objective

• structure experiential knowledge relevant for decision making

derive a similarity metric for patients who have received similar treatments

predict treatment decisions that experts are likely to recommend

Step 2: Similarity learning based on Rx decision point

Step 4: **Experience Engine Rx decision**



Test Set: 596 decisions for an online expert opinion service e.g. primary Sx, 1st line CT, etc.

Machine Learning to uncover nonlinear similarities (e.g., similar treatments for younger patients with multiple comorbidities and elderly patients) **Multiple Similarity Distance Metrics evaluated** Bhattacharya, Eskin, Goodall, etc. Multiclass Classification Algorithms evaluated XGB, CART, SVM, kNN, c5.0 etc.

to compare improvements in accuracy with machine learning

Baseline (weighted random guess) vs XE accuracy

- 1. XE algorithms are significantly more accurate than baseline at predicting actual treatment decisions recommended by experts (Table 1)
- 2. There is great variation in the number of treatment choices for each decision point 3. Accuracy was higher for decision points with fewer treatment choices

XE accuracy for Standard (common, evidence-based) vs All treatments

- 1. The most frequent treatments decisions recommended across all decision points were standard evidence based therapies
- 2. XE algorithms are more accurate at predicting standard treatments than all treatments. Accuracy is significantly higher for decision points with a larger number of nonstandard treatment choices
- 3. XE learned to weigh features relating to comorbidities and toxicities when recommending nonstandard treatments

This presentation is the intellectual property of the author/presenter. Contact them at gitika@navyanetwork.com for permission to reprint and/or distribute

Methodology

- **Training Set:** 743 breast cancer tumor board decisions at 2 tertiary care centers
- **Target Of Prediction**: Treatment class (e.g. Anthra) and the specific regimen(e.g. AC)
- Primary Endpoint: Accuracy (AUC) of XE's predicted and expert's actual Rx decision
- Navya Ontology:690 structured features designed specifically for breast cancer decisions
- Data Grouping for nonlinear similarities: 13 groups by treatment decision point



Weighted Random Guessing was used as a baseline for prediction

- Winning algorithms maximized accuracy (AUC) for each treatment decision point

to Age

Results

Table 1 – Accuracy by Rx Decisions

Treatment Decision Point (N)	# of Rx Choices	Baseline Weighted Random Guess	XE Accuracy (AUC) ±CI for All Rx	XE Accuracy (AUC) ±CI for Standard Rx
Primary Breast Surgery (80)	13	27% ±9.7	69% ±10.1 *	69% ±10.1
Primary Lymph Node	7	65%	72%	82%
Surgery (80)		±10.4	±9.8	±8.4
Adjuvant HER2- by Chemo	12	32%	79%	88%
Class (88)		±9.7	±8.5 *	±6.7
Adjuvant HER2- by Chemo	38	12%	31%	70%
Regimen (88)		±6.7	±9.6 *	±9.5 *
Adjuvant HER2+ by Chemo	9	18%	58%	70%
Class (62)		±9.5	±12.2 *	±11.4
Adjuvant HER2+ by Chemo	30	9%	50%	88%
Regimen (62)		±7.1	±12.4 *	±8 *
Adjuvant Premenopausal	7	70%	75%	99%
Hormone (22)		±19.1	±18	±4.1 *
Adjuvant Postmenopausal	13	53%	99%	99%
Hormone (66)		±12	±2.3 *	±2.4
Adjuvant Radiation (107)	16	32% ±7.2	82% ±4.8 *	93% ±6.5 *

* No overlap between confidence intervals- Baseline vs XE All and XE All vs Standard

Conclusion

- Experience Engine using machine learning on past expert decisions can predict treatments that experts are likely to recommend for a new patient
- Despite the limited dataset, the Experience Engine learned features that experts strongly consider when making decisions
- By including complex decisions that consider toxicities and morbidities, a rich new source of knowledge complementing evidence can be created
- The Experience Engine has the potential to analyze variations in decision making at expert practices, assess when to recommend nonstandard treatments, and serve as a training tool for new oncologists to make expert grade treatment decisions

